Interpretation - What is the low-frequency spectrum obtained by SpaceX for Starlink Mobile?
路透社2026/10/09 13:19Harshita Mary Varghese, Reuters, October 9 - SpaceX SPCX.O has agreed to acquire a portfolio of low-band spectrum licenses covering the entire United States, in a deal reportedly valued at $8 billion. The company is seeking to expand its business beyond satellite internet and become a major competitor in the U.S. mobile market. SpaceX revealed its plans to enter the mobile service sector during its first earnings call in August. This announcement briefly weighed on the company’s stock price, and shares of the three major U.S. wireless carriers—AT&T, T-Mobile, and Verizon—were also affected as investors assessed the potential competitive threat. What is low-band spectrum? Low-band spectrum refers to radio waves that travel further and penetrate buildings better compared to higher frequencies, making them suitable for wide-area mobile network coverage. In contrast, mid-band and high-band spectrums can transmit more data at faster speeds but have a smaller coverage area. SpaceX has agreed to purchase up to 14 MHz of paired 800 MHz low-band spectrum licenses from Grain Management and plans to develop a hybrid architecture for Starlink Mobile, combining terrestrial infrastructure with satellite connectivity. How is the U.S. spectrum licensing system structured? Commercial spectrum is a scarce resource in the U.S., regulated by the Federal Communications Commission (FCC), which typically allocates licenses for specific frequencies and geographic areas via auctions or other authorization processes. License holders must comply with technical rules and deployment requirements, and transfers of licenses usually require regulatory approval before obligations are fulfilled. The spectrum license deal recently struck by SpaceX is pending FCC approval. Which low-band spectrum do the three major carriers hold? AT&T’s low-band spectrum includes the 700 MHz and 850 MHz bands, as well as 600 MHz spectrum licenses acquired this July through the purchase of EchoStar. Verizon holds spectrum in the 700 MHz and 850 MHz bands, while T-Mobile’s low-band holdings include 600 MHz and 700 MHz spectrum. What are the plans for STARLINK MOBILE? The company plans to integrate these spectrum licenses into its next-generation satellite system, while also deploying terrestrial radio equipment and antennas on communication towers and rooftops. The FCC this week approved Starlink Mobile’s application for its second-generation (Gen2) satellite constellation, authorizing SpaceX to launch 15,000 satellites globally optimized for the 2 GHz spectrum.
Harshita Mary Varghese
Reuters, October 9 - SpaceX SPCX.O has agreed (link) to acquire a nationwide portfolio of low-band spectrum licenses in the United States, a deal reportedly valued at $8 billion. The company is seeking to expand its business beyond satellite internet and become a major competitor in the U.S. mobile market.
The company first revealed plans to enter the mobile services sector during its August earnings call. The announcement temporarily weighed down (link) its stock price, and also impacted shares of the three major U.S. wireless carriers — AT&T, T-Mobile, and Verizon — as investors assessed the potential competitive threat.
What is low-band spectrum?
Low-band spectrum refers to radio waves that travel longer distances and penetrate buildings more effectively than high-band spectrum, making it ideal for broad mobile network coverage.
This is different from mid- and high-band spectrums, which can transmit more data at higher speeds but cover smaller areas.
SpaceX has agreed to acquire up to 14 MHz of paired 800 MHz low-band spectrum licenses from Grain Management and plans to develop a hybrid architecture for Starlink Mobile, combining terrestrial infrastructure with satellite connectivity.
How does the U.S. spectrum licensing system work?
Commercial spectrum is a scarce resource in the U.S., regulated by the Federal Communications Commission (FCC), which typically assigns licenses for specific frequencies and geographic regions through auctions or other authorization processes.
License holders must comply with technical rules and deployment requirements, but transfers of licenses generally require regulatory approval before obligations are fulfilled.
SpaceX's recently agreed spectrum license deal is awaiting FCC approval.
What spectrum do the three major carriers hold?
AT&T's low-band spectrum portfolio includes the 700 MHz and 850 MHz bands, as well as the 600 MHz licenses acquired by purchasing EchoStar in July.
Verizon holds spectrum in the 700 MHz and 850 MHz bands, while T-Mobile's low-band spectrum includes the 600 MHz and 700 MHz bands.
What are the plans for STARLINK MOBILE?
The company plans to integrate this spectrum into its next-generation satellite system, while deploying terrestrial radio equipment and antennas on cell towers and rooftops.
The Federal Communications Commission (FCC) this week approved the second-generation (Gen2) Starlink Mobile satellite constellation application, authorizing SpaceX to launch 15,000 satellites globally optimized for the 2 GHz spectrum.
(To facilitate users whose native language is not English, Reuters automatically translates its reports into several other languages. Because automated translation may be inaccurate or lack necessary context, Reuters does not guarantee the accuracy of automated translations and provides them for reader convenience only. Reuters accepts no responsibility for any harm or loss arising from the use of automated translation features.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
WTI holds steady as traders weigh US-Iran tensions and supply risks
Japan: Bond outflows reshape global yields - Commerzbank
BUZZ - JPMorgan gives “overweight” rating to LSD-based therapies, Definium stock rises
Latest Updates, October 9th - ** Definium Therapeutics (DFTX.O) shares rose 7.4% to $36.7 ** If the rally holds, the stock is set for its biggest single-day gain since June ** JPMorgan initiated coverage of the stock with an "Overweight" rating and a target price of $84 ** The bank stated that Definium’s lead candidate drug, DT120 ODT, has the potential to transform the treatment landscape for neuropsychiatric disorders ** Based on current data, the institution considers DT120 ODT (an LSD oral formulation for the treatment of major depressive disorder and generalized anxiety disorder) to be a "de-risked asset" ** The new target price implies a 145.7% upside from the latest closing price ** "While changes in the macro environment may present potential investment risks to the sector, we believe the positives for Definium outweigh the negatives," the bank stated ** A period of "frequent landmark events" is expected ahead, including plans to submit a new drug application to the FDA in the first half of 2027 ** The bank projects that total sales of DT120 orally disintegrating tablets (ODT) will approach $5 billion by 2035 ** Including intraday volatility, the stock has more than doubled in value year-to-date (For the convenience of non-English speakers, Reuters has automated this report’s translation into several other languages. Due to possible errors in automated translation or lack of full context, Reuters does not guarantee the accuracy of the automated translation and provides it solely as a convenience to readers. Reuters accepts no liability for any damage or loss arising from the use of automated translation.)
BUZZ - UBS raises AbbVie’s target price, citing expansion of its core business beyond the immunology drug sector
On October 9, UBS raised its target price for AbbVie (ABBV.N) from $260 to $275, stating that investors' focus is shifting from blockbuster drugs Skyrizi and Rinvoq to the next wave of growth in its immunology business. UBS also noted that other projects in AbbVie’s R&D pipeline remain robust. It expects strong third-quarter performances from Skyrizi and Rinvoq, with respective sales reaching $5.7 billion and $2.7 billion. Special attention was given to upcoming combined treatment data of Skyrizi for Crohn's disease and ulcerative colitis, with mid-stage trial results to be released later this month. UBS believes that the drug lutikizumab, for inflammatory skin diseases, has a potential market size of $1-2 billion, and pointed out that Rinvoq sales are likely to surpass $500 million. The report also mentioned positive late-stage clinical data for cancer drugs Epkinly and etentamig, as well as the recent launch of the Parkinson’s disease medication tavapadon. UBS expects third-quarter earnings per share (EPS) to reach $3.76, within AbbVie’s forecast range of $3.73 to $3.77. Including intraday fluctuations, AbbVie’s stock has risen 21% so far this year. (For the convenience of non-English speakers, Reuters provides automated translation of its reports into several other languages. Due to potential inaccuracies or lack of required context in automated translations, Reuters does not guarantee the accuracy of these texts and is not liable for any damage or loss arising from their use. The translations are provided solely for readers' convenience.)
Crypto prices
More
